CClinicalTrials.gg
Not yet recruitingNCT06680115Updated Nov 8, 2024

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

A Phase 2 interventional study of Sintilimab in Nasopharyngeal Carcinoma (NPC), sponsored by First Affiliated Hospital of Guangxi Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by First Affiliated Hospital of Guangxi Medical University · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.

02

Conditions studied

  • Nasopharyngeal Carcinoma (NPC)
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 150 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

First Affiliated Hospital of Guangxi Medical University is the lead sponsor of 41 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
  2. Age≥18 years;
  3. Staging TanyN3M0 (AJCC/UICC 9th edition) ;
  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  5. White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;
  6. Transaminases≤2.5 times the upper limit of normal, total bilirubin \<1.5 times the upper limit of normal;
  7. Creatinine clearance ≥60 ml/min;
  8. Signed informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. HBsAg positive and HBV DNA >1×103 copy/ml;
  2. Patients with positive HCV antibody test results;
  3. Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
  4. History of interstitial lung disease;
  5. Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
  6. Have received or will receive live vaccine within 30 days before signing the informed consent;
  7. Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
  8. Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
  9. The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
  10. Human immunodeficiency virus (HIV) infection;
  11. Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Sintilimab

    Drug: Sintilimab

  • No intervention
    Control

Interventions

  • DrugSintilimab

    Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine

06

What researchers measure

Primary outcomes

  1. Failure-free survival

    Time frame: 2 years

Secondary outcomes

  1. Overall survival

    Time frame: 2 years

  2. Distant failure-free survival

    Time frame: 2 years

  3. Locoregional failure-free survival

    Time frame: 2 years

07

Study locations

1 site
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06680115
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Nov 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 8, 2024

Study contacts

Rensheng Wang
Contact
13807806008@163.com
86-0771-5356509

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion